

antagonist, which down-regulate the function of AM, factor H, and the AM/fH complex has been achieved. Collectively, the invention provides methods for treating conditions such as cancer or diabetes, via antibodies and small molecule antagonists.

Adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor, driving neoplastic proliferation. Experimental models for use in identifying the role of AM in pancreatic physiology have been validated and are available for licensing. The interesting observations show that AM inhibits insulin secretion in a dose-dependent manner. Further experiments have shown that a neutralizing antibody up-regulates insulin release at least five-fold, an effect that is reversed with the addition of synthetic AM.

#### **Novel Inhibitors of p53 for Treatment of Neurodegenerative Disorders, Myocardial Infarction and Other Tissue Insults**

Nigel H. Greig, et al. (NIA)

Serial No. 60/216,388, filed July 6, 2000

*Licensing Contact:* Norbert Pontzer; 301/496-7736, ext. 284; e-mail: pontzern@nih.gov

The tumor suppressor protein p53 is a key modulator of stress responses, and activation of p53 precedes apoptosis (programmed cell death) in many cell types. Conditions that stress tissue, such as deposition of amyloid b-peptide, may thus cause tissue degeneration through activation or up-regulation of p53. This invention provides novel inhibitors of p53 and methods of using these inhibitors for the prevention or treatment of the stress related tissue degeneration observed in Alzheimer's disease, myocardial infarction and stroke. In vitro and ex vivo studies demonstrated that p53 inhibition protected nerve cells from toxic insults that otherwise induced programmed cell death. In a rat model of stroke, p53 inhibition produced a 50% reduction in stroke volume.

Dated: May 17, 2001.

#### **Jack Spiegel,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 01-13346 Filed 5-25-01; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Heart, Lung, and Blood Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel NHLBI, National Research Service Training, SEP (K's).

*Date:* June 28-29, 2001.

*Time:* 7 PM to 5 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* Chevy Chase Holiday Inn, 5520 Wisconsin Ave., Chevy Chase, MD 20815.

*Contact Person:* Roy L. White, PhD, Review Branch, NIH, NHLBI, Rockledge Building II, 6701 Rockledge Drive, Room 7196, Bethesda, MD 20892, 301-435-0291.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: May 22, 2001.

#### **LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 01-13335 Filed 5-25-01; 8:45 am]

**BILLING CODE 4140-01-M**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Heart, Lung, and Blood Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel ACTION-A-CHF trial Investigating Outcomes, of Exercise Training.

*Date:* June 19, 2001.

*Time:* 2 to 5.

*Agenda:* To review and evaluate grant applications.

*Place:* 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

*Contact Person:* Joyce A. Hunter, PhD, Review Branch, Room 7194, Division of Extramural Affairs, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20872.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: May 22, 2001.

#### **LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 01-13336 Filed 5-25-01; 8:45 am]

**BILLING CODE 4140-01-M**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Heart, Lung, and Blood Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel RFA: HL-01-004 (Blood and Marrow Transplant Clinical Research Network).

*Date:* June 28-29, 2001.

*Time:* 7 PM to 5 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* Marriott Wardman Park Hotel, 2660 Woodley Road NW., Washington, DC 20008.

*Contact Person:* Diane M. Reid, MD, Review Branch, Room 7182, Division of Extramural Affairs, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, (301) 435-0277.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: May 22, 2001.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 01-13338 Filed 5-25-01; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Drug Abuse Initial Review Group, Treatment Research Subcommittee.

*Date:* June 7-8, 2001.

*Time:* 9 AM to 3 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* Radisson Barcelo Hotel, 2121 P Street NW, Washington, DC 20037.

*Contact Person:* Kesinee Nimit, MD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547, (301) 435-1432.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* National Institute on Drug Abuse Initial Review Group, Health Services Research Subcommittee.

*Date:* June 7-8, 2001.

*Time:* 9 AM to 5 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* Radisson Barcelo Hotel, 2121 P Street NW, Washington, DC 20037.

*Contact Person:* Marina L. Volkov, Ph.D., Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547, (301) 435-1433.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel, Treatment Research.

*Date:* June 7, 2001.

*Time:* 1 PM to 4 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* Radisson Barcelo Hotel, 2121 P Street NW, Washington, DC 20037.

*Contact Person:* Mark R. Green, Ph.D., Chief, CEASRB, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, Suite 3158, 6001 Executive Boulevard, Bethesda, MD 20892-9547, (301) 435-1431.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel, International Studies on Drug Abuse and HIV/AIDS.

*Date:* June 27, 2001.

*Time:* 8 AM to 6 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* Courtyard by Marriott, 1600 Rhode Island Ave., NW., Washington, DC 20037.

*Contact Person:* William C. Grace, Ph.D., Deputy Director, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547, (301) 443-2755.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel, Center Review Committee.

*Date:* July 9, 2001.

*Time:* 8:30 AM to 4 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* Ritz-Carlton Pentagon City, 1250 S. Hayes Street, Arlington, VA 22202.

*Contact Person:* Rita Liu, Ph.D., Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547, (301) 443-2620.

*Name of Committee:* National Institute on Drug Abuse Initial Review Group, Medication Development Research Subcommittee.

*Date:* July 9-10, 2001.

*Time:* 9 AM to 6 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* The Westin Grand, 2350 M Street, NW, Washington, DC 20037.

*Contact Person:* Khurshed Asghar, Ph.D., Chief, Basic Sciences Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547, (301) 443-2620.

*Name of Committee:* National Institute on Drug Abuse Initial Review Group, Training and Career Development Subcommittee.

*Date:* July 10-11, 2001.

*Time:* 8 AM to 6 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* Ritz Carlton-Pentagon City, Arlington, VA.

*Contact Person:* Mark Swieter, Ph.D., Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547, (301) 435-1389.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel, Medication Development.

*Date:* July 10, 2001.

*Time:* 10 AM to 3 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* The Westin Grand Hotel, 2350 M Street, NW, Washington, DC 20037.

*Contact Person:* Rita Liu, Ph.D., Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547, (301) 443-2620.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel, Responding to Club Drugs and Other Emerging and Current Drug Abuse Trends.

*Date:* July 11-12, 2001.

*Time:* 8 AM to 5 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* The Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, DC 20037.

*Contact Person:* William C. Grace, Ph.D., Deputy Director, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547, (301) 443-2755.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel, Research on GHB and its Precursors.

*Date:* July 16-17, 2001.

*Time:* 9 AM to 5 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* Ritz-Carlton Pentagon City, 1250 S. Hayes Street, Arlington, VA 22202.

*Contact Person:* Rita Liu, Ph.D., Health Scientist Administrator, Office of Extramural